CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND) — grant history
Latest income
£4.9m
Grants listed (FY2023)
13
Listed grants total
£1.1m
Accounts grants total
£1.5m
listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2023 accounts
Application guidance — from the funder’s own website
- What they don’t fund: We do not generally fund basic laboratory research, including animal studies. Animal studies may be funded as part of later stage research prior to embarking on a proof of concept clinical trial.
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Kings College London - Base Editing of RDEB fibroblasts | FY2023 | £703k | Research projects |
| University of Colorado – Spray on Skin | FY2023 | £155k | Research projects |
| Kings College London - Nanocol | FY2023 | £95k | Research projects |
| PASTE – Superexon Replacement | FY2023 | £50k | Research projects |
| UCL Gene Editing | FY2023 | £49k | Research projects |
| Universidad Carlos III de Madrid - Gene Editing Trial | FY2023 | £14k | Research projects |
| University of Minnesota - Nanocol | FY2023 | £200 | Research projects |
| Inserm - Oligo | FY2023 | £0 | Research projects |
| Inserm - EB Graft | FY2023 | £0 | Research projects |
| Inserm - SIRNA | FY2023 | £0 | Research projects |
| Great Ormond Street - Gene Therapy | FY2023 | £0 | Research projects |
| Thomas Jefferson - Rigosertib | FY2023 | £0 | Research projects |
| St Thomas’ Hospital, London - Rigosertib | FY2023 | £0 | Research projects |
| Kings College London | FY2022 | £208k | Base Editing of RDEB fibroblasts |
| EB Graft | FY2022 | £151k | |
| Great Ormond Street | FY2022 | £140k | Mission EB |
| Debra UK | FY2022 | £127k | Gene therapy |
| St Thomas' Hospital, London | FY2022 | £127k | Rigosertib |
| Thomas Jefferson | FY2022 | £127k | Rigosertib |
| University of Minnesota | FY2022 | £83k | Nanocol |
| Kings College London | FY2022 | £82k | Nanocol |
| Stanford University | FY2022 | £77k | EB IPS Cell Consortium |
| Oligo | FY2022 | £32k | |
| Universidad Carlos III de Madrid | FY2022 | £27k | Gene Editing Trial |
| UCL | FY2022 | £18k | Gene Editing |
| Kings College London - Nanocol | FY2021 | £195k | |
| UCL Gene Editing | FY2021 | £150k | |
| University of Minnesota - Next Gene Genome Sequencing/Nanocol | FY2021 | £113k | |
| Universidad Carlos III de Madrid - Gene Editing Trial | FY2021 | £106k | |
| Great Ormond Street - Mission EB | FY2021 | £100k | |
| EB Therapeutics | FY2021 | £92k | |
| Stanford University - EB IPS Cell Consortium | FY2021 | £65k | |
| EB Graft | FY2021 | £37k | |
| Colorado Gates | FY2021 | £36k |